Kandy Boy pledges $1M to Last Prisoner Project, SNDL and Valens agree to merge, TILT passes final inspections
Kandy Boy has announced a new partnership with the Last Prisoner Project. They will be giving away 1,000,000 free gummy samples through their website and have pledged to donate $1 for each free gummy sample claimed.
“Kandy Boy is committed to having a positive impact on the future of the cannabis industry and the broad benefits it is bringing to society,” stated Benjamin Boyce, CEO & Co-Founder of Kandy Boy. “We cannot change what has happened to these people and communities due to failed cannabis policy, but we can work to bring restitution to those who have been harmed by supporting their release from incarceration and giving them a new lease on life. We are committed to advancing our shared vision to release those behind bars for non-violent cannabis offenses and we’re excited to leverage our free samples to help scale our impact.”
SNDL Inc and The Valens Company Inc have entered into an agreement combine their businesses. Under the agreement SNDL will acquire all issued and outstanding common shares and issue SNDL shares as per the Offer Exchange Ratio.
“We are thrilled to bring together two best-in-class cannabis companies that have extremely complementary assets to create a true market leader. Valens is one of the fastest growing branded cannabis companies in Canada with a focus on innovation and investing in low-cost automated manufacturing assets,” announced Tyler Robson, Chief Executive Officer of The Valens Company. “With SNDL’s exceptional balance sheet and largest cannabis retail network in Canada we look forward to taking Valens’ brands to new heights and unlocking 2.0 products for the SNDL platform. We believe the pro forma company provides investors with attractive exposure not only to the highest revenue generating cannabis company in Canada trading well under its tangible book value but also a dominant platform that can become a global leader in cannabis.”
Leviathan Natural Health Products Inc has completed the acquisition of all issued and outstanding shares in Tirthankar Ltd. The deal will see $1.8M in cash consideration and 15.75M common shares to be issued to Tirthankar shareholders.
“Securing a significant foothold in Ontario’s cannabis retail market is an important milestone for the Company,” said Martin J. Doane, CEO of Leviathan. “The Tirthankar team has a portfolio of well-positioned cannabis retail stores strategically placed in previously underserved cities and towns across the province. The Company’s management team looks forward to working with Tirthankar to build out its strong, revenue-generating platform.”
Press release: https://www.newsfilecorp.com/release/135110/Leviathan-Completes-Acquisition-of-Cannabis-Retailer-Tirthankar
Pathway Health Corp is thrilled to welcome Mr. Mark Goldhar to the Board of Directors as well as the Audit and Compensation and Governance committees.
“Mark’s experience in raising capital, providing strategic advice for entrepreneurial companies in the finance, digital media and cannabis space speaks for itself,” relayed Ken Yoon, Chief Executive Officer of Pathway. “His perspective on our growth and strategic initiatives will be immensely impactful.”
Press release: https://www.newswire.ca/news-releases/pathway-announces-appointment-of-mark-goldhar-as-board-member-884723230.html
TILT Holdings Inc subsidiary Commonwealth Alternative Care Inc has passed their final inspections and is now approved to commence operations of its Cambridge, MA medical cannabis dispensary. The dispensary will open September 2, 2022.
“Located right in the heart of Inman Square, we are excited to open the doors of our third medical dispensary in Massachusetts this week, just before the holiday long weekend,” stated Gary Santo, Chief Executive Officer of TILT. “Adding Cambridge to our existing retail facilities in Brockton and Taunton strengthens TILT’s position as a resource throughout patients’ cannabis journeys.”
PharmaDrug Inc is happy to announce they are meeting their research goals and are able to file for a provisional patent on a novel DMT based glaucoma treatment in Q4 2022. Pharmadrug has partnered with several universities in various research agreements.
“With a focused biotech strategy now in place, PharmaDrug can accelerate its push forward in its psychedelic programs,” said Daniel Cohen, CEO and Chairman of PharmaDrug. “Utilizing bottom-up fundamental research and innovation fueled by world class collaborations, the Company plans to continue to find novel uses and unique delivery forms of DMT to treat unmet medical needs.”
Press release: https://www.newsfilecorp.com/release/134793/PharmaDrug-Advances-Psychedelics-Pharmaceutical-Program-Focused-on-DMT-and-DMT-Analogues